Pyrrolidonecarboxylic Acid
In clinical developmentAlso known as (-)-2-pyrrolidone-5-carboxylic acid, (S)-(-)-2-pyrrolidone-5-carboxylic acid, (S)-pyroglutamic acid, 5-L-oxoproline+11 more
(-)-2-pyrrolidone-5-carboxylic acid, (S)-(-)-2-pyrrolidone-5-carboxylic acid, (S)-pyroglutamic acid, 5-L-oxoproline, 5-Pyrrolidone-2-carboxylic acid, 5-oxo-2-pyrrolidinecarboxylic acid, 5-oxo-L-proline, Glutimic acid, L-5-Pyrrolidone-2-carboxylic acid, L-pyroglutamic acid, L-pyrrolidone carboxylic acid, PCA, PIDOLIC ACID, Pyroglutamic acid, PYRROLIDONE CARBOXYLIC ACID.
Recent clinical, regulatory, research and industry developments relating to this drug.
Protein-responsive gut hormone tachykinin directs food choice and impacts lifespan.
Effect of Tab Block and Patient Controlled Analgesia in Cesarean Section
Effect of Continue Rhomboid Intercostal and Subserratus Plane Block in Thorocotomy
Effectiveness of Quadratus Lumborum Block After Nephrectomy
Patient Controlled Paravertebral Analgesia for Video-assisted Thoracoscopic Surgery
Effect of Thoracic Epidural Analgesia on Bowel Function Recovery in Major Upper Abdominal Surgeries
Hypokalemia and Intravenous Patient Controlled Analgesia
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes4
Journals, researchers & institutions
- Nature metabolism1
- Ahrentløv N1
- Frederiksen AS1
- Halberg KV1
- Imig C1
- John A1
- Koyama T1
- Kubrak O1
- Lassen M1
- The Novo Nordisk Foundation1
- University of Copenhagen1
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials